579 results on '"Waterhouse D"'
Search Results
2. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma
3. EP.17E.01 Cost-Effectiveness Analysis of Sotorasib vs. Adagrasib in KRAS G12c-Mutated Previously Treated NSCLC.
4. Unmet needs, quality of life and psychological distress: insights regarding head and neck cancer patients in a rural setting
5. Suboptimal Exposure to Anti‐TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy
6. Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
7. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model
8. Exploring the interactions between blackcurrant polyphenols, pectin and wheat biopolymers in model breads; a FTIR and HPLC investigation
9. Interference Effects in Argon Auger Coincidence Spectra
10. Morbidity, mortality, and cost impact of stage b and stage c heart failure: comparative analysis to underline the clinical and economic need for heart failure prevention strategy.: 1236
11. Unmet needs, quality of life and psychological distress: insights regarding head and neck cancer patients in a rural setting.
12. P60.13 MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study
13. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol
14. The Composition of the Scent of the Green Vegetable bug, Nezara viridula
15. Fire-Arms in Japanese History: With Notes on a Japanese Wall Gun
16. Twelve Japanese Prints
17. Stability of antioxidants in an apple polyphenol–milk model system
18. Australiaʼs first CyberKnife: Preliminary experience
19. An examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population
20. P09.56 Real-World Outcomes Among Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
21. Characterisation of a multi-view fringe projection system based on the stereo matching of rectified phase maps
22. MO01.05 Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in the Era of Immunotherapy (IO)
23. MO01.06 Real-World Outcomes of Immunotherapy-Based Regimens in First-Line Advanced Non-Small Cell Lung Cancer
24. Boost focal therapy for prostate cancer using I-125, biological imaging and radiobiological indices: 026 – Scientific Paper
25. Anthony Reeve Woodhill, 1900-1965. (Memorial Series No. 21)
26. Comparison of fruit traits for Chinese cherry cultivars
27. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
28. Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur
29. Real-world survival with first-line (1L) chemotherapy in patients (PTS) with advanced non-small cell lung cancer (ANSCLC)
30. Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer
31. A simple and inexpensive method to routinely produce customized neck supports for patient immobilization during radiotherapy
32. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer
33. Studies on chemical bath deposited cadmium sulphide films by buffer solution technique
34. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
35. P2.06-04 Treatment Patterns and Outcomes of Advanced Malignant Pleural Mesothelioma (MPM) Patients in a Community Practice Setting
36. P1.14-18 ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK+) NSCLC Patients in the US Community Oncology Setting
37. OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
38. P588Foie gras in the right ventricle
39. Intra-operative Radiotherapy with a Miniature X-ray Source
40. 45 Progression of cardiac amyloid fibril infiltration in cardiac amyloidosis using cardiac magnetic resonance
41. 1 Pictorial evolution of focal myocardial fibrosis in duchenne muscular dystrophy (DMD)
42. Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy
43. The Biological Control of Dung
44. 82P - Real-world survival with first-line (1L) chemotherapy in patients (PTS) with advanced non-small cell lung cancer (ANSCLC)
45. P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
46. P1.01-051 Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-world Setting
47. P1.03-026 Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC
48. 20 Characterizing durable targets for therapy in asymptomatic left ventricular diastolic dysfunction by sequential two-dimensional doppler-echocardiography and cardiac magnetic resonance imaging
49. Experimental comparison of photogrammetry for additive manufactured parts with and without laser speckle projection
50. Comparative efficacy and safety of nivolumab (nivo) vs relevant treatments (txs) in pretreated squamous (SQ) advanced non-small cell lung cancer (aNSCLC): Results from a systematic literature review (SLR) and indirect treatment comparisons (ITCs) of randomized controlled trials (RCTs)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.